EUVIMEDEUVIMED entdecken
Crossref

Exploring host epigenetic enzymes as targeted therapies for visceral leishmaniasis: in silico design and in vitro efficacy of KDM6B and ASH1L inhibitors

Mukul Dutta, Tooba Qamar, Unnati Kushavah, Mohammad Imran Siddiqi, Susanta Kar

Molecular Diversity · 2024

DOI: 10.1007/s11030-024-10824-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diversity, 2024. Verfasst von Mukul Dutta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases & Immunology Division, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Jadavpur, Kolkata, 700032, India. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Leishmaniasis, Visceral, Jumonji Domain-Containing Histone Demethylases, Antiprotozoal Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Department of Science and Technology, Ministry of Science and Technology, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In order to combat various infectious diseases, the utilization of host-directed therapies as an alternative to chemotherapy has gained a lot of attention in the recent past, since it bypasses the existing limitations of conventional therapies. The use of host epigenetic enzymes like histone lysine methyltransferases and lysine demethylases as potential drug targets has successfully been employed for controlling various inflammatory diseases like rheumatoid arthritis and acute leukemia. In our earlier study, we have already shown that the functional knockdown of KDM6B and ASH1L in the experimental model of visceral leishmaniasis has resulted in a significant reduction of organ parasite burden. Herein, we performed a high throughput virtual screening against KDM6B and ASH1L using > 53,000 compounds that were obtained from the Maybridge library and PubChem Database, followed by molecular docking to evaluate their docking score/Glide Gscore. Based on their docking scores, the selected inhibitors were later assessed for their in vitro anti-leishmanial efficacy. Out of all inhibitors designed against KDM6B and ASH1L, HTS09796, GSK-J4 and AS-99 particularly showed promising in vitro activity with IC50 < 5 µM against both extracellular promastigote and intracellular amastigote forms of L. donovani. In vitro drug interaction studies of these inhibitors further demonstrated their synergistic interaction with amphotericin-B and miltefosine. However, GSK-J4 makes an exception by displaying an in different mode of interaction with miltefosine. Collectively, our in silico and in vitro studies acted as a platform to identify the applicability of these inhibitors targeted against KDM6B and ASH1L for anti-leishmanial therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Docking SimulationLeishmaniasis, VisceralJumonji Domain-Containing Histone DemethylasesAntiprotozoal AgentsDrug DesignEnzyme InhibitorsHistone-Lysine N-MethyltransferaseHumansEpigenesis, GeneticComputer SimulationLeishmania donovaniDNA-Binding ProteinsMolecular Targeted TherapyTranscription FactorsAnimalsBenzazepinesPyrimidines

Stichwörter der Autor:innen

ASH1LEpigenetic enzymesIsobologramKDM6BMolecular dockingVisceral leishmaniasis (VL)

Substanzen

Jumonji Domain-Containing Histone DemethylasesAntiprotozoal AgentsEnzyme InhibitorsHistone-Lysine N-MethyltransferaseGSK-J4DNA-Binding ProteinsTranscription FactorsBenzazepinesPyrimidines

Autor:innen und Institutionen

  • Infectious Diseases & Immunology Division, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Jadavpur, Kolkata, 700032, India.
  • Molecular Microbiology & Immunology Division, CSIR-Central Drug Research Institute, BS-10/1, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
  • Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow, Uttar Pradesh, 226014, India.
  • Biochemistry and Structural Biology Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, India.
  • Infectious Diseases & Immunology Division, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Jadavpur, Kolkata, 700032, India. susantakar@iicb.res.in.

Förderung

  • Department of Science and Technology, Ministry of Science and Technology, India

Zitieren

APA

Dutta, M., Qamar, T., Kushavah, U., Siddiqi, M. I., & Kar, S. (2024). Exploring host epigenetic enzymes as targeted therapies for visceral leishmaniasis: in silico design and in vitro efficacy of KDM6B and ASH1L inhibitors. Molecular Diversity. https://doi.org/10.1007/s11030-024-10824-w

Vancouver

Dutta M, Qamar T, Kushavah U, Siddiqi MI, Kar S. Exploring host epigenetic enzymes as targeted therapies for visceral leishmaniasis: in silico design and in vitro efficacy of KDM6B and ASH1L inhibitors. Molecular Diversity. 2024. doi:10.1007/s11030-024-10824-w

BibTeX
@article{Dutta2024,
  author = {Dutta, Mukul and Qamar, Tooba and Kushavah, Unnati and Siddiqi, Mohammad Imran and Kar, Susanta},
  title = {Exploring host epigenetic enzymes as targeted therapies for visceral leishmaniasis: in silico design and in vitro efficacy of KDM6B and ASH1L inhibitors},
  journal = {Molecular Diversity},
  year = {2024},
  doi = {10.1007/s11030-024-10824-w}
}
Kostenlos starten →